Ignite Creation Date:
2024-05-06 @ 10:28 AM
Last Modification Date:
2024-10-26 @ 12:31 PM
Study NCT ID:
NCT03271554
Status:
COMPLETED
Last Update Posted:
2022-11-18
First Post:
2017-09-01
Brief Title:
Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea
Sponsor:
Organization:
Hoffmann-La Roche
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
355
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 43532 |
Who Masked List: